【摘要】 目的考察生血宁片对非透析慢性肾脏病肾性贫血患者的临床疗效。方法 94例患者随机分为实验组(53例)与对照组(41例),实验组给予生血宁片,对照组给予琥珀酸亚铁片,疗程12周。然后,监测EPO用量、Hb水平、铁代谢指标(SI、SF、TSAT、TIBC)、肝肾功能及不良反应。结果治疗6、8、10、12周后,2组Hb水平显著高于筛选期(P<0. 05),但组间无显著差异(P>0. 05);治疗12周后,2组SI、SF、TSAT显著高于筛选期(P<0. 05),但组间无显著差异(P>0. 05);治疗8、12周后,实验组EPO用量显著低于对照组(P<0. 05)。2组血常规参数无明显变化,并且未发现与研究药物有关的不良反应。结论生血宁片可维持非透析慢性肾脏病肾性贫血患者铁代谢指标,减少EPO用量,安全性良好。更多还原

【Abstract】 AIM To investigate the clinical effects of Shengxuening Tablets on renal anemia patients with nondialysis chronic kidney disease. METHODS Ninety-four patients randomly assigned into trial group( n = 53) and control group( n = 41) went on 12-week treatment course of Shengxuening Tablets( the trial group),or Ferrous Succinate Tablets( the control group). Subsequently,Hb level,iron metabolism indices( SI,SF,TSAT,TIBC),kidney and liver function were detected. EPO comsumption and adverse events were recorded. RESULTS After6-week,8-week,10-week,12-week treatment,significantly higher Hb levels than those in the screening period were demonstrated in the two groups( P < 0. 05) with no significant inter-group difference( P > 0. 05). After 12-week treatment,markedly higher SI,SF,TSAT than those in the screening period were observed in the two groups( P<0. 05) with no significant inter-group difference( P>0. 05). After 8-week,12-week treatment,obviously lower EPO consumption in the trial group than that in the control group was found as well( P<0. 05). No obvious changes in routine blood parameters, and no drug-related adverse reactions were observed in the two groups.CONCLUSION With good safety,Shengxuening Tablets maintain iron metabolism and reduce EPO consumption in managing renal anemia patients with non-dialysis chronic kidney disease.更多还原